{{Rsnum
|rsid=2298383
|Gene=ADORA2A
|Chromosome=22
|position=24429543
|Orientation=plus
|GMAF=0.4816
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=ADORA2A,SPECC1L-ADORA2A
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 15.5 | 49.1 | 35.5
| HCB | 20.6 | 53.4 | 26.0
| JPT | 18.2 | 50.9 | 30.9
| YRI | 66.1 | 33.9 | 0.0
| ASW | 55.4 | 33.9 | 10.7
| CHB | 20.6 | 53.4 | 26.0
| CHD | 25.7 | 41.0 | 33.3
| GIH | 58.4 | 36.6 | 5.0
| LWK | 43.5 | 50.9 | 5.6
| MEX | 12.3 | 42.1 | 45.6
| MKK | 38.8 | 44.1 | 17.1
| TSI | 16.2 | 51.5 | 32.3
| HapMapRevision=28
}}Variation at this SNP, [[rs2298383]], appears to influence how an individual responds to moderate levels (150mg) of [[caffeine]].{{PMID|18305461|OA=1
}}

{{PMID Auto
|PMID=20334879
|Title=Adenosine A(2A) receptor gene: Evidence for association of risk variants with panic disorder and anxious personality
}}

{{PharmGKB
|RSID=rs2298383
|Name_s=ADORA2A: g.4216080C>T
|Gene_s=ADORA2A
|Feature=
|Evidence=PubMed ID:18539621
|Annotation=Risk or phenotype-associated allele: rs2298383 T allele. Phenotype: Carriers of 1 or 2 copies of the T allele for rs2298383 showed increased risk of any (OR = 2.23, CI 1.03-5.07, p = 0.03) or gastrointestinal-specific (OR = 2.65, CI = 0.8-11.35, p = 0.09) adverse events. Study size: 309 RA patients, including 147 good MTX responders, 101 MTX inefficacy failures, and 61 adverse event (AE) MTX failures (e.g. gastrointestinal (n = 24), abnormal liver function tests (n = 20), haematological (n = 7), skin rashes (n = 6), and other (n = 17). Study population/ethnicity: Rheumatoid arthritis (RA) patients aged over 18 yrs, of White Caucasian ethnic origin, classified as having RA according to ARA criteria that were retrospectively recruited from University Hospital of North Staffordshire (UHNS) and Central Manchester and Manchester Children&apos;s University Hospitals Trust (CMMC) in England. Significance metric(s): OR = 2.23-2.65, p = 0.03-0.09. Type of association: GN; PD; TOX; ADR.
|Drugs=methotrexate
|Drug Classes=
|Diseases=Arthritis, Rheumatoid; Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165110741
}}

{{PMID Auto
|PMID=22336631
|Title=Caffeine increases tear volume depending on polymorphisms within the adenosine A2a receptor gene and cytochrome P450 1A2.
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2298383
|overall_frequency_n=59
|overall_frequency_d=128
|overall_frequency=0.460938
|n_genomes=36
|n_genomes_annotated=0
|n_haplomes=50
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=23535492
|Title=ADORA2A polymorphism predisposes children to encephalopathy with febrile status epilepticus
|OA=1
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}